We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.99 | -2.13% | 91.36 | 91.31 | 91.40 | 93.23 | 90.75 | 92.85 | 348,041 | 20:37:47 |
From May 2022 to May 2024
By Clarence Leong
BioNTech SE has acquired a manufacturing facility in Singapore from Novartis AG as the German biotechnology company aims to expands its presence in Asia.
The plant will be BioNTech's first mRNA manufacturing facility in Singapore and serve as its regional headquarters, BioNTech said Monday.
The facility, slated to be fully operational in late 2023, will have an expected annual production capacity of "up to several hundred million doses of mRNA-based vaccines," the company said. It will also create more than 100 jobs in the city-state by 2024, it said.
The project supports the company's growing pipeline of mRNA-based vaccines and therapeutics across Asia-Pacific for commercial and clinical scale, and production could expand to other drug classes such as cell therapies, BioNTech said.
BioNTech didn't disclose financial details of the deal.
Write to Clarence Leong at clarence.leong@wsj.com
(END) Dow Jones Newswires
November 13, 2022 23:29 ET (04:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
